Enrique Cadenas
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Enrique Cadenas has a total of 112 co-authors. Here are the top co-authors by number of shared publications:
- Fei Yin
Center for Innovation in Brain Science, University of Arizona, Tucson, USA
12 shared publications - Harsh Sancheti
Department of Pharmacology & Pharmaceutical Sciences, School of Pharmacy, University of Southern California, Los Angeles, California 90089, United States
6 shared publications Derick Han
5 shared publicationsHarsh Sancheti
Medtronic Neurovascular, Medtronic Inc., Irvine, CA, United States of America
5 shared publicationsAlberto Boveris
University of Buenos Aires
4 shared publicationsIshan Patil
Pharmacology & Pharmaceutical Sciences, School of Pharmacy, University of Southern California, Los Angeles, CA, United States of America
4 shared publications
Latest Publications
- Open Access
- 4 July 2025
- Published by MDPI AG in Pathophysiology
- Vol. 32 (3) , 34
Thiamine Deficiency and Neuroinflammation Are Important Contributors to Alcohol Use Disorder
Despite the growing morbidity associated with alcohol use disorder (AUD), current FDA-approved therapeutics fail to adequately address the condition. This is in part due to the complex systemic effects of ethanol (EtOH), which have particularly negative consequences on the gut–liver–brain axis. Importantly, two systemic mechanisms underlying the progression of AUD remain underemphasized in therapeutic development: thiamine deficiency and neuroinflammation. Alcohol-induced thiamine deficiency leads to reduced activity of key metabolic enzymes, thereby resulting in energy deficits, oxidative stress, and severe clinical implications. EtOH also activates TLR4 and NLRP3, both of which play critical roles in the regulation of neuroimmune responses. While research directly investigating the relationship between thiamine deficiency and neuroinflammation is still in its early stages, our review highlights the emerging connections between these two seemingly distinct pathomechanisms. Additionally, potential therapeutic approaches and targets for addressing AUD at a systemic level are discussed.
- 4 July 2025
- Published by MDPI AG in Pathophysiology
- Vol. 32 (3) , 34
Open AccessThiamine Deficiency and Neuroinflammation Are Important Contributors to Alcohol Use Disorder
Despite the growing morbidity associated with alcohol use disorder (AUD), current FDA-approved therapeutics fail to adequately address the condition. This is in part due to the complex systemic effects of ethanol (EtOH), which have particularly negative consequences on the gut–liver–brain axis. Importantly, two systemic mechanisms underlying the progression of AUD remain underemphasized in therapeutic development: thiamine deficiency and neuroinflammation. Alcohol-induced thiamine deficiency leads to reduced activity of key metabolic enzymes, thereby resulting in energy deficits, oxidative stress, and severe clinical implications. EtOH also activates TLR4 and NLRP3, both of which play critical roles in the regulation of neuroimmune responses. While research directly investigating the relationship between thiamine deficiency and neuroinflammation is still in its early stages, our review highlights the emerging connections between these two seemingly distinct pathomechanisms. Additionally, potential therapeutic approaches and targets for addressing AUD at a systemic level are discussed.
- 10 August 2023
- Published by Elsevier in Free Radical Biology and Medicine
- Vol. 206, 191-192
In Memoriam: Pierre Cillard (1942–2023)
- 10 August 2023
- Published by Elsevier in Free Radical Biology and Medicine
- Vol. 206, 191-192
In Memoriam: Pierre Cillard (1942–2023)
- 1 April 2023
- Published by SAGE Publications in Antioxidants & Redox Signaling
- Vol. 38 (10-12) , 768-774
Lester Packer: On His Life and His Legacy
Lester Packer was an exceptional scientific leader, whose radiant personality inspired and encour-aged generations of students and scientists for research to pursue oxidants and antioxidants in biol-ogy and medicine. For the FORUM dedicated to Professor Packer, we here describe key aspects of his professional career, from the early years at Brooklyn College, Yale University and the Johnson Research Foundation at Philadelphia to his long-term base at the University of California, at UC Berkeley. The concept of the ‘Antioxidant Network’ formed the core of his activities in later years. His welcoming and integrative personality led to a worldwide network of colleagues, starting with the Bay Area Oxygen Club, which turned into the Oxygen Club of California (OCC), and his lead-ership in the Society for Free Radical Research-International (SFRR-I). To illustrate his warmth and outreach, which enabled him to form borderless global collaborations, we conclude with words from some of his many friends also from outside academia: Lester Packer’s legacy.
- 1 April 2023
- Published by SAGE Publications in Antioxidants & Redox Signaling
- Vol. 38 (10-12) , 768-774
Lester Packer: On His Life and His Legacy
Lester Packer was an exceptional scientific leader, whose radiant personality inspired and encour-aged generations of students and scientists for research to pursue oxidants and antioxidants in biol-ogy and medicine. For the FORUM dedicated to Professor Packer, we here describe key aspects of his professional career, from the early years at Brooklyn College, Yale University and the Johnson Research Foundation at Philadelphia to his long-term base at the University of California, at UC Berkeley. The concept of the ‘Antioxidant Network’ formed the core of his activities in later years. His welcoming and integrative personality led to a worldwide network of colleagues, starting with the Bay Area Oxygen Club, which turned into the Oxygen Club of California (OCC), and his lead-ership in the Society for Free Radical Research-International (SFRR-I). To illustrate his warmth and outreach, which enabled him to form borderless global collaborations, we conclude with words from some of his many friends also from outside academia: Lester Packer’s legacy.
- Open Access
Using the Cyclotide Scaffold for Targeting Biomolecular Interactions in Drug Development
This review provides an overview of the properties of cyclotides and their potential for developing novel peptide-based therapeutics. The selective disruption of protein–protein interactions remains challenging, as the interacting surfaces are relatively large and flat. However, highly constrained polypeptide-based molecular frameworks with cell-permeability properties, such as the cyclotide scaffold, have shown great promise for targeting those biomolecular interactions. The use of molecular techniques, such as epitope grafting and molecular evolution employing the cyclotide scaffold, has shown to be highly effective for selecting bioactive cyclotides.
Open AccessUsing the Cyclotide Scaffold for Targeting Biomolecular Interactions in Drug Development
This review provides an overview of the properties of cyclotides and their potential for developing novel peptide-based therapeutics. The selective disruption of protein–protein interactions remains challenging, as the interacting surfaces are relatively large and flat. However, highly constrained polypeptide-based molecular frameworks with cell-permeability properties, such as the cyclotide scaffold, have shown great promise for targeting those biomolecular interactions. The use of molecular techniques, such as epitope grafting and molecular evolution employing the cyclotide scaffold, has shown to be highly effective for selecting bioactive cyclotides.
- Open Access
- 6 May 2022
- Published by SAGE Publications in Antioxidants & Redox Signaling
- Vol. 36 (13-15) , 813-823
Redox Pioneer: Professor Valerian Kagan
Professor Valerian Kagan (PhD, 1972, MV Lomonosov Moscow State University; DSci, 1981, USSR, Academy of Sciences, Moscow) is recognized as a Redox Pioneer because he has published 4 articles in the field of redox biology that have been cited >1000 times and 138 articles in this field have been cited between 100 and 924 times. The central and most important impact of Dr. Kagan's research is in the field of redox lipidomics—a term coined for the first time by Dr. Kagan in 2004—and consequently the definition of signaling pathways by oxidatively modified phospholipids; this acquires further significance considering that oxygenated phospholipids play multifunctional roles as essential signals coordinating metabolism and physiology. Some examples are the selective oxidation of cardiolipin (CL) by a cytochrome c peroxidase activity leading to the activation of the intrinsic apoptotic pathway; the hydroperoxy-arachidonoyl/adrenoyl phosphatidylethanolamine (PE) species, driven by 15-lipoxygenases (15-LOX), as death signals leading to ferroptotic cell death; the regulation of ferroptosis by iNOS/NO • in pro-inflammatory conditions by a novel mechanism (realized via interactions of 15-LOX reaction intermediates formed from arachidonoyl phosphatidylethanolamine [PE] species) and Ca 2+ -independent phospholipase A2 (iPLA 2 β; via elimination of peroxidized PE); the involvement of oxygenated (phospho)lipids in immunosuppression by myeloid cells in the tumor microenvironment; hydrolysis of peroxidized CL by Ca 2+ -independent phospholipase A2 (iPLA 2 γ) leading to pro- and anti-inflammatory signals and lipid mediators. Kagan continues his investigations to decipher the roles of enzyme-linked oxygenated phospholipids. Antioxid. Redox Signal. 36, 813–823.
- 6 May 2022
- Published by SAGE Publications in Antioxidants & Redox Signaling
- Vol. 36 (13-15) , 813-823
Open AccessRedox Pioneer: Professor Valerian Kagan
Professor Valerian Kagan (PhD, 1972, MV Lomonosov Moscow State University; DSci, 1981, USSR, Academy of Sciences, Moscow) is recognized as a Redox Pioneer because he has published 4 articles in the field of redox biology that have been cited >1000 times and 138 articles in this field have been cited between 100 and 924 times. The central and most important impact of Dr. Kagan's research is in the field of redox lipidomics—a term coined for the first time by Dr. Kagan in 2004—and consequently the definition of signaling pathways by oxidatively modified phospholipids; this acquires further significance considering that oxygenated phospholipids play multifunctional roles as essential signals coordinating metabolism and physiology. Some examples are the selective oxidation of cardiolipin (CL) by a cytochrome c peroxidase activity leading to the activation of the intrinsic apoptotic pathway; the hydroperoxy-arachidonoyl/adrenoyl phosphatidylethanolamine (PE) species, driven by 15-lipoxygenases (15-LOX), as death signals leading to ferroptotic cell death; the regulation of ferroptosis by iNOS/NO • in pro-inflammatory conditions by a novel mechanism (realized via interactions of 15-LOX reaction intermediates formed from arachidonoyl phosphatidylethanolamine [PE] species) and Ca 2+ -independent phospholipase A2 (iPLA 2 β; via elimination of peroxidized PE); the involvement of oxygenated (phospho)lipids in immunosuppression by myeloid cells in the tumor microenvironment; hydrolysis of peroxidized CL by Ca 2+ -independent phospholipase A2 (iPLA 2 γ) leading to pro- and anti-inflammatory signals and lipid mediators. Kagan continues his investigations to decipher the roles of enzyme-linked oxygenated phospholipids. Antioxid. Redox Signal. 36, 813–823.
- 25 April 2022
- Published by Elsevier in Archives of Biochemistry and Biophysics
- Vol. 726, 109214
On 'Production of superoxide radicals and hydrogen peroxide by NADH-ubiquinone reductase and ubiquinol-cytochrome c reductase from beef-heart mitochondria' by Enrique Cadenas, Alberto Boveris, C. Ian Ragan and Andres O.M.Stoppani
- 25 April 2022
- Published by Elsevier in Archives of Biochemistry and Biophysics
- Vol. 726, 109214
On 'Production of superoxide radicals and hydrogen peroxide by NADH-ubiquinone reductase and ubiquinol-cytochrome c reductase from beef-heart mitochondria' by Enrique Cadenas, Alberto Boveris, C. Ian Ragan and Andres O.M.Stoppani
- 29 March 2022
- Published by Elsevier in Archives of Biochemistry and Biophysics
- Vol. 721, 109197
Publisher Notice
- 29 March 2022
- Published by Elsevier in Archives of Biochemistry and Biophysics
- Vol. 721, 109197
Publisher Notice
- Open Access
- 1 July 2021
- Published by Elsevier in The American Journal of Pathology
- Vol. 191 (7) , 1240-1254
Inhibition of Estrogen-Related Receptor α Blocks Liver Steatosis and Steatohepatitis and Attenuates Triglyceride Biosynthesis
- 1 July 2021
- Published by Elsevier in The American Journal of Pathology
- Vol. 191 (7) , 1240-1254
Open AccessInhibition of Estrogen-Related Receptor α Blocks Liver Steatosis and Steatohepatitis and Attenuates Triglyceride Biosynthesis
- 10 January 2021
- Published by SAGE Publications in Antioxidants & Redox Signaling
- Vol. 34 (2) , 137-153
Mitochondria as Target for Tumor Management of Hemangioendothelioma
Aims: Hemangioendothelioma (HE) may be benign or malignant. EOMA cells are validated to study mechanisms in HE. This work demonstrates that EOMA cells heavily rely on mitochondria to thrive. Thus, a combination therapy including weak X-ray therapy (XRT, 0.5Gy) and a standardized natural berry extract (NBE) that is known to be effective in managing experimental HE and has been awarded with Food and Drug Administration - Investigational New Drug Application (FDA-IND # 140318) for studies on infantile hemangioma was tested. Results: NBE treatment alone selectively attenuated basal oxygen consumption rate (OCR) of EOMA cells. NBE significantly sensitized EOMA, but not MAE, cells to XRT-dependent attenuation of mitochondrial respiration and ATP production. Combination treatment selectively and potently influenced mitochondrial dynamics in EOMA cells such that fission was augmented. Markers of mitochondrial fission were induced by the said combination therapy. This was achieved by lowering of mitochondrial Sirtuin 3 (SIRT3) causing increased phosphorylation of AMP-activated protein kinase (AMPK). A key role of SIRT3 in loss of EOMA cell viability caused by the combination therapy was evident when pyrroloquinoline quinone, an inducer of SIRT3, pre-treatment rescued these cells. Innovation and Conclusion: Mitochondria-targeting NBE significantly extended survival of HE-affected mice. The beneficial effect of combination therapy was, however, far more potent with 3-fold increase in murine survival. Mitochondria-targeted antitumor therapies warrant further consideration.
- 10 January 2021
- Published by SAGE Publications in Antioxidants & Redox Signaling
- Vol. 34 (2) , 137-153
Mitochondria as Target for Tumor Management of Hemangioendothelioma
Aims: Hemangioendothelioma (HE) may be benign or malignant. EOMA cells are validated to study mechanisms in HE. This work demonstrates that EOMA cells heavily rely on mitochondria to thrive. Thus, a combination therapy including weak X-ray therapy (XRT, 0.5Gy) and a standardized natural berry extract (NBE) that is known to be effective in managing experimental HE and has been awarded with Food and Drug Administration - Investigational New Drug Application (FDA-IND # 140318) for studies on infantile hemangioma was tested. Results: NBE treatment alone selectively attenuated basal oxygen consumption rate (OCR) of EOMA cells. NBE significantly sensitized EOMA, but not MAE, cells to XRT-dependent attenuation of mitochondrial respiration and ATP production. Combination treatment selectively and potently influenced mitochondrial dynamics in EOMA cells such that fission was augmented. Markers of mitochondrial fission were induced by the said combination therapy. This was achieved by lowering of mitochondrial Sirtuin 3 (SIRT3) causing increased phosphorylation of AMP-activated protein kinase (AMPK). A key role of SIRT3 in loss of EOMA cell viability caused by the combination therapy was evident when pyrroloquinoline quinone, an inducer of SIRT3, pre-treatment rescued these cells. Innovation and Conclusion: Mitochondria-targeting NBE significantly extended survival of HE-affected mice. The beneficial effect of combination therapy was, however, far more potent with 3-fold increase in murine survival. Mitochondria-targeted antitumor therapies warrant further consideration.